Skip to main content

Errata - English

PDF CSV October 18, 2023 through October 18, 2025 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
STEAROYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol USP36–NF31 2250 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Analysis: Change
(VSVB)
to:
(VBVS)
AND
Line 12 of Analysis: Change
VS = Titrant volume consumed by the Sample… Read More
STEARYL ALCOHOL SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> USP36–NF31 2252 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 14 of Analysis: Change
[(VSVB) × N × F]/W
to:
[(VBVS) × N × Mr]/W
AND
Line 15 of Analysis: Change… Read More
BUTABARBITAL SODIUM TABLETS Identification, Infrared Absorption <197K> USP36–NF31 2716 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 5 of Test specimen: Change
Proceed as directed for Column Partition Chromatography under Chromatography <621>, packing the chromatographic tube as follows.
to:
Pack a chromatographic tube as follows.
CAFFEINE CITRATE INJECTION Assay USP36–NF31 2732 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of Chromatographic system: Change
150-cm column
to:
15-cm column
CAFFEINE CITRATE ORAL SOLUTION Assay USP36–NF31 2733 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of Chromatographic system: Change
150-cm column
to:
15-cm column
CARISOPRODOL, ASPIRIN, AND CODEINE PHOSPHATE TABLETS USP Reference standards <11> USP36–NF31 2813 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of USP Codeine N-Oxide RS: Change
C18H21O4
to:
C18H21NO4
CLAVULANATE POTASSIUM IMPURITIES/Organic Impurities/Procedure 3: Limit of Aliphatic Amines USP36–NF31 3022 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 In the definition list in Analysis: Change
CU = nominal concentration of Clavulanate Potassium in the Standard solution
to:
CU = nominal concentration of Clavulanate Potassium in the Sample solution
DROSPIRENONE IMPURITIES/Organic Impurities/Procedure 2 USP36–NF31 3349 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 In footnote b of Table 4: Change
5β,17β-Dihydroxy-6β,7β:15β,16β-dimethylene-17α-pregnan-21-carboxylic acid, γ-lactone.
to:
5β,17-Dihydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregnan-21-carboxylic acid, γ-lactone.
ESOMEPRAZOLE MAGNESIUM SPECIFIC TESTS/Color of Solution USP36–NF31 3464 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample solution: Change
20 mg/mL of Esomeprazole Magnesium in methanol
to:
20 mg/mL of Esomeprazole Magnesium in methanol, filtered
ETHIODIZED OIL INJECTION Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 3505 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or
FERUMOXSIL ORAL SUSPENSION Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 3572 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or
MERCAPTOPURINE TABLETS IMPURITIES/Organic Impurities/Procedure USP36–NF31 4249 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 6 of Sample stock solution: Change
Dilute with water to volume.
to:
Dilute with Solution A to volume.
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2/System suitability USP36–NF31 4327 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Capacity factor: Change
NMT 2
to:
NLT 2
OCTOCRYLENE Identification, Ultraviolet Absorption <197U> USP36–NF31 4557 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 4: Change
Absorptivities, calculated on the as-is basis,
to:
Absorptivity at 303 nm, calculated on the as-is basis,
OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC SOLUTION Identification USP36–NF31 4652 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
A volume of Ophthalmic Solution, equivalent to about 2.5 mg of oxymetazoline hydrochloride, responds to the Identification test under Oxymetazoline Hydrochloride Nasal Solution.
to:
Place a volume of Ophthalmic Solution, equivalent to about 2.5 mg of… Read More
POLYVINYL ALCOHOL SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911>, Rotational Rheometer Methods <912>, and Rolling Ball Viscometer Method <913> USP36–NF31 4830 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
and
to:
or
QUININE SULFATE IMPURITIES/Dihydroquinine Sulfate USP36–NF31 4995 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 5 of Analysis: Change
Result = (rU/rS) × 100
to:
Result = rU/(rU + rS) × 100
RIFAMPIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL HYDROCHLORIDE TABLETS Assay for rifampin, isoniazid, and pyrazinamide USP36–NF31 5047 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 12 of Procedure: Change
the Standard preparation and the Assay preparation, respectively.
to:
the Assay preparation and the Standard preparation, respectively.
RIMEXOLONE OPHTHALMIC SUSPENSION Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 5053 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or
RIVASTIGMINE TARTRATE CHEMICAL INFORMATION USP36–NF31 5073 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
398.41
to:
400.42
SALICYLIC ACID USP Reference standards <11> USP36–NF31 5098 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of USP Salicylic Acid Related Compound A RS: Change
[CAS-99-96-7].
to:
[99-96-7].
AND
Line 3 of USP Salicylic Acid Related Compound B RS: Change
C8H6O4
to:
C8H6O5
TERAZOSIN CAPSULES PERFORMANCE TESTS/Dissolution <711>/Test 1/Spectrometric conditions USP36–NF31 5308 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Analytical wavelength: Change
UV 245 nm
to:
UV 246 nm
AND
Line 3 of Cell length: Change
0.2 cm for Capsules labeled to contain 10 mg
to:
0.5 cm for Capsules labeled to contain 10 mg
COMPOUND UNDECYLENIC ACID OINTMENT Assay for zinc undecylenate USP36–NF31 5516 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 15 of Procedure: Change
431.94 is the molecular weight of zinc undecylenate;
to:
Mr is the molecular weight of zinc undecylenate, 431.94;
AND
Line 16 of Procedure: Change
65.39 is the atomic weight of zinc;
to:
Ar… Read More
URSODIOL TABLETS IMPURITIES/Organic Impurities/Procedure USP36–NF31 5520 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Sample solution: Change
Tablets, equivalent to about 25 mg of ursodiol,
to:
Tablets, equivalent to about 250 mg of ursodiol,
BACLOFEN ASSAY/Procedure/Chromatographic system First Supplement to USP36–NF31 5951 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Column: Change
250-cm
to:
25.0-cm
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities, Procedure 2 First Supplement to USP36–NF31 5996 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3: Change the section head
Isosorbide mononitrate related compound A stock solution:
to:
Isosorbide mononitrate related compound A standard stock solution:
AND
Line 7: Change the section head
Isosorbide dinitrate stock solution:
to:
Isosorbide… Read More
LOPINAVIR AND RITONAVIR TABLETS PERFORMANCE TESTS/Dissolution <711> First Supplement to USP36–NF31 6005 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Tolerances: Change
80.0%
to:
80%
QUININE SULFATE TABLETS ASSAY/Procedure First Supplement to USP36–NF31 6046 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 4 of Analysis: Change
dihydroquinone sulfate
to:
dihydroquinine sulfate
BETHANECHOL CHLORIDE IMPURITIES/Heavy Metals, Method 1 <231> Second Supplement to USP36–NF31 6568 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Test preparation: Change
Bethacholine Chloride
to:
Bethanechol Chloride
FILGRASTIM ASSAY/Potency Second Supplement to USP36–NF31 6606 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 7 of Preparation of cells for analysis: Change
Column 1 is filled with 50 L of Medium B.
to:
Column 1 is filled with 50 µL of Medium B.
PANCURONIUM BROMIDE INJECTION IMPURITIES/Organic Impurities Second Supplement to USP36–NF31 6677 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Footnote a of Table 1: Change
Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide.
to:
Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl.
POLYMYXIN B SULFATE IMPURITIES/Organic Impurities Second Supplement to USP36–NF31 6686 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Buffer, Mobile phase, Diluent, Sensitivity solution,
to:
Buffer, Mobile phase, Diluent, Standard solution, Sensitivity solution,
AND
Line 1 of Samples in Analysis: Change
Standard solution, Sample solution, and Read More
STINGING NETTLE COMPOSITION/Content of Total Amino Acids USP36–NF31 1604 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Reagent solution: Change
Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin,
to:
Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
POWDERED STINGING NETTLE COMPOSITION/Content of Total Amino Acids USP36–NF31 1606 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Reagent solution: Change
Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin,
to:
Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
POWDERED STINGING NETTLE EXTRACT COMPOSITION/Content of Total Amino Acids USP36–NF31 1608 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Reagent solution: Change
Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin,
to:
Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
GLYCERYL DISTEARATE ASSAY/Procedure/Chromatographic system USP36–NF31 2029 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Column temperature: Change
Column temperature: 40°
to:
Temperatures
Detector: 40°
Column: 40°
SODIUM HYDROXIDE ASSAY/Procedure USP36–NF31 2203 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Analysis: Change
= volume of Titrant consumed by the Sample to the first endpoint (mL)
to:
= volume of Titrant consumed by the Sample to the second endpoint (mL)
AMOXICILLIN IMPURITIES/Organic Impurities/Procedure USP36–NF31 2477 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Acceptance criteria: Change
[Note—The reporting limit is 0.03% of the amoxicillin peak from the Standard solution. ]
to:
[Note—The reporting limit is 0.03 times the amoxicillin peak from the Standard solution. ]
BETAMETHASONE SODIUM PHOSPHATE Identification/B. Thin-Layer Chromatographic Identification Test <201> USP36–NF31 2645 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Test solution: Change
1 mg per mL.
to:
1 mg per mL in methanol.
CALCIUM CARBONATE IMPURITIES USP36–NF31 2747 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Acceptance criteria in Limit of Fluoride: Change
50 ppm
to:
NMT 50 ppm
AND
Line 1 of Acceptance criteria in Mercury, Method IIa <261>: Change
0.5 ppm
to:
NMT 0.5 ppm
CEFDINIR CAPSULES IMPURITIES/Organic Impurities/Table 2 USP36–NF31 2850 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Row 16 of Column 1: Change
Cefdinir impurity 2e
to:
Cefdinir impurity 2f
AND
Row 21 of Column 1: Change
Cefdinir impurity 3e
to:
Cefdinir impurity 3f
CLARITHROMYCIN FOR ORAL SUSPENSION ASSAY/Procedure USP36–NF31 3018 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Change the subsection head
Buffer:
to:
Buffer A:
AND
After the Buffer A subsection: Add
Buffer B: 0.067 M dibasic potassium phosphate
AND
Line 1 of Mobile phase: Change
Methanol and Buffer
to:
Methanol and Buffer ARead More
CLARITHROMYCIN EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 4 USP36–NF31 3019 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Standard solution: Change
and Medium (96:4).
to:
and Medium (4:96).
DACARBAZINE FOR INJECTION USP Reference standards <11> USP36–NF31 3137 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of USP Dacarbazine Related Compound B RS: Change
C4H3N5O 137.10
to:
C4H3N5O · H2O 155.12
CRYOPRESERVED HUMAN FIBROBLAST-DERIVED DERMAL SUBSTITUTE Total collagen content USP36–NF31 3155 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 7 of Collagen calibration standards: Change
by adding 25 mL, 50 mL, 100 mL, and 200 mL,
to:
by adding 25 μL, 50 μL, 100 μL, and 200 μL,
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES Assay USP36–NF31 3276 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION Assay USP36–NF31 3276 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
DIPHENHYDRAMINE HYDROCHLORIDE ORAL SOLUTION Assay USP36–NF31 3277 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
EDETATE DISODIUM ASSAY/Procedure USP36–NF31 3370 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 5: Delete
Titrimetric system
(See Titrimetry <541>.)
Mode: Direct titration
Titrant: 0.1 N sodium hydroxide VS
Endpoint detection: Visual
EDETATE DISODIUM ASSAY/Procedure USP36–NF31 3370 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 16 of Analysis: Change
Calculate the percentage of edetate disodium
to:
Calculate the weight of edetate disodium
AND
Line 19 of Analysis: Change
Result = (VT/VU) × W × (Mr1/Mr2) ×… Read More